Bisfosfonatlar; osteoporoz, multipl miyelom, hiperkalsemi, Paget hastalığı, fibröz displazi gibi metabolik kemik hastalıklarının tedavisinde kemik rezorpsiyonunu önlemede oldukça etkilidir. Bununla birlikte, kemikte yeniden yapılanmayı baskılayarak bazı komplikasyonlara neden olmaktadır. Bifosfonatların çenelerde görülen en önemli yan etkisi ise osteonekroza sebep olmasıdır. Bifosfonat kullanımına bağlı olarak çenelerde osteonekroz gelişiminde birçok faktör rol oynayabilmektedir. Uyumu kötü olan protez kullanımı bu faktörler arasında yer almaktadır. Bu çalışmada, 62 yaşındaki erkek olgunun alt çenesinde hareketli protez kullanımı sonucu oluşan bifosfonata bağlı osteonekroz tedavisinin anlatılması amaçlanmıştır.
Anahtar Kelimeler: Bifosfonat; osteonekroz; hareketli parsiyel protez
Bisphosphonates; is very effective in preventing bone resorption in the treatment of metabolic bone diseases such as osteoporosis, multiple myeloma, hypercalcemia, Paget's disease, fibrous dysplasia. However, it causes some complications by suppressing restructuring in the bones. The most important side effect of bisphosphonates in dentistry is osteonecrosis of the jaw. Depending on the use of bisphosphonates, many factors can play a role in the development of osteonecrosis in the jaws and poor fitting prosthesis can be shown among these factors. In this case report, management of bisphosphonate related osteonecrosis in a 62 year old male patient who has removable partial denture prosthesis was described.
Keywords: Bisphosphonates; osteonecrosis; removable partial prosthesis
- Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MG, Paula LM, et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(1):14-21. [Crossref] [PubMed]
- Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol. 2004;172(2):529-32. [Crossref] [PubMed]
- Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonateassociated osteonecrosis of the jaws in breast cancer patients. Cancer. 2009;115(8):1631-7.[Crossref] [PubMed]
- Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, et al. Prevalence and risk factors of bisphosphona-teassociated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2009;54(5):1066-72.[Crossref] [PubMed]
- Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005;182(8):413-5.
- Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism ofaction and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-45. [Crossref] [PubMed] [PMC]
- Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98(3):259-60.[Crossref] [PubMed]
- Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19. [Crossref] [PubMed]
- Furukawa S, Oobu K, Moriyama M, Kawano S, Sako S, Hayashida J, et al. Oral methotrexate-related lymphoproliferative disease presenting with severe osteonecrosis of the jaw: a case report and literature review. Intern Med. 2018;57(4):575-81. [Crossref] [PubMed] [PMC]
- Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2-12. [Crossref] [PubMed]
- Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O?Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.[Crossref] [PubMed]
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-7. [Crossref]
- Weber JB, Camilotti RS, Ponte ME. Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review. Lasers Med Sci. 2016;31(6):1261-72. [Crossref] [PubMed]
- Gabbert TI, Hoffmeister B, Felsenberg D. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. J Cancer Res Clin Oncol. 2015;141(4): 749-58. [Crossref] [PubMed]
- Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008;139(1):23-30.[Crossref] [PubMed]
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medicationrelated osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-56.[Crossref] [PubMed]
- Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1-37. [Crossref] [PubMed] [PMC]
- Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014;58:126-135. [Crossref] [PubMed]
- Pichardo SE, van Merkesteyn JP. Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(3): 287-92. [Crossref] [PubMed]
- Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(1):89-90. [Crossref] [PubMed]
- Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42(3):327-9. [Crossref] [PubMed]
- Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25(1):2-10. [Crossref] [PubMed]
- Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford). 2014;53 (1):19-31. [Crossref] [PubMed]
- Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011;1218:47-54. [Crossref] [PubMed]
- Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Cranio-Maxillofac Surg. 2010;38(4): 255-9. [Crossref] [PubMed]
- Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronaterelated necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18(12): 2015-9. [Crossref] [PubMed]
- Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397-410. [Crossref] [PubMed]
- Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW, et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res. 2010;25(6):1337-49. [Crossref] [PubMed] [PMC]
- Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66(5):83947. [Crossref] [PubMed] [PMC]
- Zandi M, Dehghan A, Janbaz P, Malekzadeh H, Amini P. The starting point for bisphosphonate-related osteonecrosis of the jaw: alveolar bone or oral mucosa? A randomized, controlled experimental study. J Craniomaxillofac Surg. 2017;45(1):157-61. [Crossref] [PubMed]
- Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, et al. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg. 2010;68(11):2837-45. [Crossref] [PubMed]
- Altay MA, Tasar F, Tosun E, Kan B. Low-level laser therapy supported surgical treatment of bisphosphonate related osteonecrosis of jaws: a retrospective analysis of 11 cases. Photomed Laser Surg. 2014;32(8):468-75.[Crossref] [PubMed]
- Vescovi P, Merigo E, Manfredi M, Meleti M, Fornaini C, Bonanini M, et al. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experiences 28 cases. Photomed Laser Surg. 2008;26(1):37-46. [Crossref] [PubMed]
- Silva LF, Curra C, Munerato MS, Deantoni CC, Matsumoto MA, Cardoso CL, et al. Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. Oral Maxillofac Surg. 2016;20(1):9-17. [Crossref] [PubMed]
- Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, et al. Hyperbaric oxygen treatment and bisphosphonateinduced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg. 2007;65(7): 1321-7. [Crossref] [PubMed]
- Agrillo A, Petrucci MT, Tedaldi M, Mustazza MC, Marino SM, Gallucci C, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Craniofac Surg. 2006;17(6):1080-3. [Crossref] [PubMed]
- Ripamonti C, Maniezzo M, Ghiringhelli R, Fagnoni E, Campa T, Mariani L, et al. Medical ozoneoil suspension applications heal osteonecrosis of the jaws (ONJS) in patients treated with bisfosfonates (BPS). Preliminary results of a single institution protocol. Breast. 2009;18(Suppl 1):S67-8. [Crossref]
- Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH (1-34)]. J Oral Maxillofac Surg. 2007;65(3):573-80. [Crossref] [PubMed]
- Timurağaoğlu A, Ozkaynak C, Tuzuner S, Bostan F, Undar L. Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib. Acta Haematol. 2007;118(4):2034. [Crossref] [PubMed]
- Regezi JA, Sciubba JJ, Jordan RC. Oral Pathology: Clinical Pathologic Correlations. 6 th ed. St. Louis, Missouri: Elsevier Health Sciences; 2012. p.480. [Crossref]
- Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009;67(5 Suppl):75-84. [Crossref] [PubMed]
.: Process List